BMC Medicine:5种健康生活助你远离肠癌

2014-10-15 佚名 生物谷

近日研究发现,采用五个相结合的健康行为或可降低患肠癌的风险。德国波茨坦人类营养研究所的研究人员研究量化多个相结合的健康生活方式,观察这些生活方式对患肠癌风险的影响,他们发现这种影响对男性比女性要强。 Krasimira Aleksandrova表示:“这些数据给个人提供额外奖励,医疗专业机构和公共卫生当局为健康的生活方式行为投入资金。每个人可以贡献出很多方法以避免癌症的发生,如果健康的生活方

近日研究发现,采用五个相结合的健康行为或可降低患肠癌的风险。德国波茨坦人类营养研究所的研究人员研究量化多个相结合的健康生活方式,观察这些生活方式对患肠癌风险的影响,他们发现这种影响对男性比女性要强。

Krasimira Aleksandrova表示:“这些数据给个人提供额外奖励,医疗专业机构和公共卫生当局为健康的生活方式行为投入资金。每个人可以贡献出很多方法以避免癌症的发生,如果健康的生活方式的改变的越多,人们的身体就会越好。”

肠癌也称为结直肠癌,它在男性常见癌症中排名第二,在女性最常见癌症中排名第三,其中有55%的病例发生在北美和西欧等发达地区。先前的研究已经发现了西方人的生活方式与癌症发生频率之间的关联。然而,大多数研究都集中在单独分离的生活方式行为,如吃红肉,而很少有人知道多样复合的生活方式因素的共同影响超出了它们单个的效应。

这项研究发表在《 BMC Medicine》期刊上,其中分析的数据来自10个国家的欧洲癌症与营养前瞻性调查(EPIC)队列研究的347237名男性和女性中。该分析使用一种健康的生活方式指数。在12年的研究期间,3759例肠癌患者都被记录下来。

健康生活方式指数是由以下生活方式因素组成:健康的体重,腹部脂肪低,参与有规律的体育活动,不抽烟和少酒,和饮食富含水果、蔬菜、鱼、酸奶、坚果和种子和富含纤维的食物,少量红肉和加工肉。每个研究对象都被分到有健康因素组,没有健康因素组的研究组别中。每个参与者生成累计分数。

Krasimira Aleksandrova表示:“我们的数据证实,健康的生活方式行为越来越多,患肠癌的风险就会减少。”

研究人员发现,采用更健康的生活方式因素可降低肠癌的风险。跟只有一个健康因素的人相比,那些有复合健康因素的如2、3、4、5种健康行为的人分别有13%,21%,34%和37%的概率可减少患肠癌的风险。基于我们的研究表明,如果人们都遵循这五种健康的行为方式那么超过22%的男性和11%的女性均可以防止肠癌的发生。”

原始出处

Krasimira Aleksandrova1*, Tobias Pischon2, Mazda Jenab3, H Bas Bueno-de-Mesquita456, Veronika Fedirko37, Teresa Norat6, Dora Romaguera689, Sven Knüppel1, Marie-Christine Boutron-Ruault101112, Laure Dossus101112, Laureen Dartois101112, Rudolf Kaaks13.etc.Combined impact of healthy lifestyle factors on colorectal cancer: a large European cohort study.BMC Medicine.2014

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1974578, encodeId=86dc19e457825, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Aug 25 11:06:00 CST 2015, time=2015-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858588, encodeId=304b18585888f, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Apr 27 16:06:00 CST 2015, time=2015-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773466, encodeId=1c8a1e734668a, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Mon Feb 02 03:06:00 CST 2015, time=2015-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660882, encodeId=8d2c1660882cd, content=<a href='/topic/show?id=a38b2e8752d' target=_blank style='color:#2F92EE;'>#健康生活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27875, encryptionId=a38b2e8752d, topicName=健康生活)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48dd25178476, createdName=xiaoyang_ambs, createdTime=Tue Nov 04 05:06:00 CST 2014, time=2014-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577410, encodeId=d13715e741012, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Oct 17 00:06:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606302, encodeId=abb6160630213, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Oct 17 00:06:00 CST 2014, time=2014-10-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1974578, encodeId=86dc19e457825, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Aug 25 11:06:00 CST 2015, time=2015-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858588, encodeId=304b18585888f, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Apr 27 16:06:00 CST 2015, time=2015-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773466, encodeId=1c8a1e734668a, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Mon Feb 02 03:06:00 CST 2015, time=2015-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660882, encodeId=8d2c1660882cd, content=<a href='/topic/show?id=a38b2e8752d' target=_blank style='color:#2F92EE;'>#健康生活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27875, encryptionId=a38b2e8752d, topicName=健康生活)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48dd25178476, createdName=xiaoyang_ambs, createdTime=Tue Nov 04 05:06:00 CST 2014, time=2014-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577410, encodeId=d13715e741012, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Oct 17 00:06:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606302, encodeId=abb6160630213, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Oct 17 00:06:00 CST 2014, time=2014-10-17, status=1, ipAttribution=)]
    2015-04-27 jeanqiuqiu
  3. [GetPortalCommentsPageByObjectIdResponse(id=1974578, encodeId=86dc19e457825, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Aug 25 11:06:00 CST 2015, time=2015-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858588, encodeId=304b18585888f, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Apr 27 16:06:00 CST 2015, time=2015-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773466, encodeId=1c8a1e734668a, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Mon Feb 02 03:06:00 CST 2015, time=2015-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660882, encodeId=8d2c1660882cd, content=<a href='/topic/show?id=a38b2e8752d' target=_blank style='color:#2F92EE;'>#健康生活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27875, encryptionId=a38b2e8752d, topicName=健康生活)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48dd25178476, createdName=xiaoyang_ambs, createdTime=Tue Nov 04 05:06:00 CST 2014, time=2014-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577410, encodeId=d13715e741012, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Oct 17 00:06:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606302, encodeId=abb6160630213, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Oct 17 00:06:00 CST 2014, time=2014-10-17, status=1, ipAttribution=)]
    2015-02-02 kalseyzl
  4. [GetPortalCommentsPageByObjectIdResponse(id=1974578, encodeId=86dc19e457825, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Aug 25 11:06:00 CST 2015, time=2015-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858588, encodeId=304b18585888f, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Apr 27 16:06:00 CST 2015, time=2015-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773466, encodeId=1c8a1e734668a, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Mon Feb 02 03:06:00 CST 2015, time=2015-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660882, encodeId=8d2c1660882cd, content=<a href='/topic/show?id=a38b2e8752d' target=_blank style='color:#2F92EE;'>#健康生活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27875, encryptionId=a38b2e8752d, topicName=健康生活)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48dd25178476, createdName=xiaoyang_ambs, createdTime=Tue Nov 04 05:06:00 CST 2014, time=2014-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577410, encodeId=d13715e741012, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Oct 17 00:06:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606302, encodeId=abb6160630213, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Oct 17 00:06:00 CST 2014, time=2014-10-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1974578, encodeId=86dc19e457825, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Aug 25 11:06:00 CST 2015, time=2015-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858588, encodeId=304b18585888f, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Apr 27 16:06:00 CST 2015, time=2015-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773466, encodeId=1c8a1e734668a, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Mon Feb 02 03:06:00 CST 2015, time=2015-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660882, encodeId=8d2c1660882cd, content=<a href='/topic/show?id=a38b2e8752d' target=_blank style='color:#2F92EE;'>#健康生活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27875, encryptionId=a38b2e8752d, topicName=健康生活)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48dd25178476, createdName=xiaoyang_ambs, createdTime=Tue Nov 04 05:06:00 CST 2014, time=2014-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577410, encodeId=d13715e741012, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Oct 17 00:06:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606302, encodeId=abb6160630213, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Oct 17 00:06:00 CST 2014, time=2014-10-17, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1974578, encodeId=86dc19e457825, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Aug 25 11:06:00 CST 2015, time=2015-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858588, encodeId=304b18585888f, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Apr 27 16:06:00 CST 2015, time=2015-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773466, encodeId=1c8a1e734668a, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Mon Feb 02 03:06:00 CST 2015, time=2015-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660882, encodeId=8d2c1660882cd, content=<a href='/topic/show?id=a38b2e8752d' target=_blank style='color:#2F92EE;'>#健康生活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27875, encryptionId=a38b2e8752d, topicName=健康生活)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48dd25178476, createdName=xiaoyang_ambs, createdTime=Tue Nov 04 05:06:00 CST 2014, time=2014-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577410, encodeId=d13715e741012, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Oct 17 00:06:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606302, encodeId=abb6160630213, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Oct 17 00:06:00 CST 2014, time=2014-10-17, status=1, ipAttribution=)]

相关资讯

CSCO 2014:徐瑞华:晚期mCRC患者标准治疗失败后的新选择值得期待

CONCUR研究是靶向药物瑞格非尼在亚太区,针对转移性结直肠癌(mCRC)患者进行的一项III期研究。 2012年,在全球进行的有关瑞格非尼对经治的mCRC患者疗效的研究——CORRECT研究,发表在《柳叶刀》The Lancet杂志上,这项研究报告的结果显示,瑞格非尼是能够在经所有标准治疗方案治疗后出现进展的结直肠癌患者中,首个显示出生存获益的小分子激酶抑制剂。瑞格非尼在欧洲和美国已经被批准用

Science:MYC基因与大肠癌和前列腺癌有关

  瑞典和芬兰研究人员最新研究发现,基因组区域中一种特定核苷酸变异与大肠癌和前列腺癌患病风险有着重要联系,是引发这两种癌症的“开关”。研究报告发表在新一期美国《科学》杂志上。   瑞典卡罗林斯卡医学院和芬兰赫尔辛基大学研究人员报告说,他们在动物实验中移除了实验鼠体内存在核苷酸变异风险的基因区域“MYC335”,结果发现,其体内“MYC”的基因表达受到强烈抑制,而老鼠的健康状况并未受到负面影响。此

Cell Rep:治疗肠癌的新型靶向疗法

近日,刊登在国际杂志Cell Reports上的一篇研究论文中,来自英国贝尔法斯特女王大学的研究人员揭示了他们在治疗肠癌患者疗法上的巨大进步。研究者表示,他们发现了两个引发肠癌细胞对疗法产生耐受性的机制,相关研究由英国癌症中心提供资助。 在之前的研究中研究者发现了两个名为MEK和MET的活性基因,这两个基因可以引发肠癌细胞对癌症疗法产生耐受性。van Schaeybroeck博士表示,当肠

CSCO 2014:青年医师论坛新辅助治疗专场: 紧扣主题、各有千秋

中山大学附属肿瘤医院、青年医师论坛新辅 助治疗专场、肠癌专 场策划负责人  陈功 本次CSCO年会上,CSCO青年医师论坛的安排可谓是独具匠心。光癌种就涉及了当前最常见的几大癌种——肠癌、胃癌、乳腺癌、肺癌,而另外还值得一提的是,这次新设了一个专场——新辅助治疗专场。 求同存异·新设新辅助治疗专场 现在,很多癌种在治疗上都有一定的共性,包括共有一些通路或靶点,或有相似的治疗模式

口腔细菌可引发肠癌

人的口腔中有各种各样的细菌 日前,两项刊登在《细胞-宿主与微生物》(Cell Host & Microbe)上的最新研究,揭开了口腔内的细菌是如何触发一连串的反应而最后导致肠癌。【原文下载1】【原文下载2】 “梭杆菌(fusobacteria)”是人口腔里常见的菌群。但这两项研究显示,这种细菌可造成人体过度的免疫反应并激活肿瘤生长基因。 梭杆菌以前就被认为同肠癌发病率具有一定的联系,

研究汇总:晚期肠癌靶向治疗进展

靶向药物的出现为晚期肠癌的治疗带来了新希望,在化疗方案基础上联合靶向药物可以进一步延长患者的生存期。目前已批准用于晚期肠癌的靶向药物包括:以血管内皮生长因子(vascular enclothelial growth factor,VEGF)为靶点的单克隆抗体,代表性药物是贝伐单抗,和以表皮生长因子受体(epide111lal growlh faclor receptor